title: Investigation of sequential growth factor delivery during cuprizone challenge in mice aimed to enhance oligodendrogliogenesis and myelin repair.
abstract: Repair in multiple sclerosis involves remyelination, a process in which axons are provided with a new myelin sheath by new oligodendrocytes. Bone morphogenic proteins (BMPs) are a family of growth factors that have been shown to influence the response of oligodendrocyte progenitor cells (OPCs) in vivo during demyelination and remyelination in the adult brain. We have previously shown that BMP4 infusion increases numbers of OPCs during cuprizone-induced demyelination, while infusion of Noggin, an endogenous antagonist of BMP4 increases numbers of mature oligodendrocytes and remyelinated axons following recovery. Additional studies have shown that insulin-like growth factor-1 (IGF-1) promotes the survival of OPCs during cuprizone-induced demyelination. Based on these data, we investigated whether myelin repair could be further enhanced by sequential infusion of these agents firstly, BMP4 to increase OPC numbers, followed by either Noggin or IGF-1 to increase the differentiation and survival of the newly generated OPCs. We identified that sequential delivery of BMP4 and IGF-1 during cuprizone challenge increased the number of mature oligodendrocytes and decreased astrocyte numbers following recovery compared with vehicle infused mice, but did not alter remyelination. However, sequential delivery of BMP4 and Noggin during cuprizone challenge did not alter numbers of oligodendrocytes or astrocytes in the corpus callosum compared with vehicle infused mice. Furthermore, electron microscopy analysis revealed no change in average myelin thickness in the corpus callosum between vehicle infused and BMP4-Noggin infused mice. Our results suggest that while single delivery of Noggin or IGF-1 increased the production of mature oligodendrocytes in vivo in the context of demyelination, only Noggin infusion promoted remyelination. Thus, sequential delivery of BMP4 and Noggin or IGF-1 does not further enhance myelin repair above what occurs with delivery of Noggin alone.
authors: Centre for Neuroscience Research, Department of Anatomy and Neuroscience, University of Melbourne, Melbourne, Australia.
authors: Jennifer K
authors: JK
authors: Sabo
authors: Tim D
authors: TD
authors: Aumann
authors: Trevor J
authors: TJ
authors: Kilpatrick
authors: Holly S
authors: HS
authors: Cate
mesh_terms: D000818:Animals; D001253:Astrocytes / Q000187:drug effects; D055415:Bone Morphogenetic Protein 4 / Q000008:administration & dosage* / Q000494:pharmacology; D002352:Carrier Proteins / Q000008:administration & dosage; D002454:Cell Differentiation; D003337:Corpus Callosum / Q000187:drug effects / Q000473:pathology; D003471:Cuprizone; D003711:Demyelinating Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage; D051379:Mice; D008810:Mice, Inbred C57BL; D009186:Myelin Sheath / Q000502:physiology*; D058953:Neural Stem Cells / Q000502:physiology; D009836:Oligodendroglia / Q000187:drug effects / Q000502:physiology; D000099176:Noggin Protein
chemical_list: D055415:Bone Morphogenetic Protein 4; D002352:Carrier Proteins; D003471:Cuprizone; D007334:Insulin-Like Growth Factor I; D000099176:Noggin Protein; C525809:BMP4 protein, human
references: J Neurosci. 1995 Nov;15(11):7344-56
references: 7472488
references: Am J Pathol. 2000 Sep;157(3):933-43
references: 10980132
references: J Neurosci. 2008 May 14;28(20):5195-206
references: 18480276
references: J Am Soc Nephrol. 2006 Jun;17(6):1644-56
references: 16672319
references: Neuron. 1995 Apr;14(4):717-30
references: 7718235
references: J Neuropathol Exp Neurol. 1997 Nov;56(11):1191-201
references: 9370229
references: Ann Neurol. 2004 Apr;55(4):458-68
references: 15048884
references: Annu Rev Neurosci. 2008;31:535-61
references: 18558866
references: J Immunol. 2010 Mar 1;184(5):2348-54
references: 20139275
references: Injury. 2011 Aug;42(8):796-802
references: 21367413
references: J Neuroimmunol. 2005 Nov;168(1-2):40-5
references: 16120466
references: J Neurosci. 2000 Aug 1;20(15):5703-8
references: 10908609
references: J Neurosci. 2011 Aug 24;31(34):12068-82
references: 21865450
references: Mol Endocrinol. 2008 May;22(5):1238-50
references: 18292241
references: Mol Cell Neurosci. 2002 Jan;19(1):32-42
references: 11817896
references: Biomaterials. 2011 Jan;32(2):565-78
references: 20889201
references: J Neurosci. 2011 Oct 5;31(40):14182-90
references: 21976503
references: J Neurosci. 2003 Aug 20;23(20):7710-8
references: 12930811
references: J Neurochem. 2010 Oct;115(1):11-22
references: 20193041
references: Nat Rev Neurosci. 2008 Nov;9(11):839-55
references: 18931697
references: Endocr Rev. 2002 Dec;23(6):824-54
references: 12466191
references: Mult Scler. 2002 Feb;8(1):24-9
references: 11936485
references: Cancer Res. 2010 Nov 15;70(22):9106-17
references: 21062988
references: Glia. 2007 Aug 15;55(11):1099-107
references: 17577243
references: Development. 2004 Sep;131(17):4131-42
references: 15280210
references: Neuron. 1993 Apr;10(4):729-40
references: 8386530
references: Cell. 1992 Jul 10;70(1):31-46
references: 1623522
references: J Neurosci. 2011 Mar 23;31(12):4504-10
references: 21430151
references: J Neurosci. 2002 Oct 1;22(19):8574-85
references: 12351731
references: Nat Neurosci. 2007 Aug;10(8):990-1002
references: 17618276
references: J Neurosci Res. 2002 Jul 15;69(2):207-16
references: 12111802
references: Tissue Eng Part A. 2011 May;17(9-10):1181-9
references: 21142700
references: Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6190-4
references: 7541143
references: J Cell Biol. 2004 Jan 5;164(1):111-22
references: 14709544